GPO hearing details
Executive Summary
Senate Judiciary/Antitrust Subcommittee is understood to be looking at April 30 as date for hearing on group purchasing organization practices. Witnesses are likely to include GPO executives (possibly Novation and Premier). General Accounting Office plans to submit preliminary findings from study of GPO practices. Primary focus of hearings is complaints by small medical device manufacturers about contracting practices, but investigations have spilled over to the pharmaceutical side (11"The Pink Sheet" April 1, p. 6)...
You may also be interested in...
APP Accounts For 1% Of Premier Drug Spend: Response To Times Article
American Pharmaceutical Partners accounts for 1% of drugs purchased by Premier, the company said
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.